Lexeo Therapeutics Inc. has announced the commencement of an underwritten public offering of its common stock and pre-funded warrants, alongside a concurrent private placement to Balyasny Asset Management. In the private placement, Lexeo will sell shares of common stock and, in lieu of common stock, pre-funded warrants to purchase common stock. The completion of the public offering is not contingent on the private placement, and both transactions are subject to market and other customary conditions. All shares and pre-funded warrants to be sold in the offering will be issued by Lexeo. The company also intends to grant underwriters a 30-day option to purchase additional shares of common stock.